Abstract
No-reflow phenomenon is a consequence of percutaneous coronary intervention (PCI) which arises most of the time in the setting of myocardial infarction, but can be also the consequence of PCI in stable angina patients (rotatablator ablation technique or angioplasty in saphenous vein grafts). In this review, we summarize two ways of treating the noreflow according to the current literature. First through the pharmacological approach where several compounds have been assessed like adenosine, nitruprusside, verapamil, nicorandil, dipyridamole, epinephrine or cyclosporine. Second through the mechanical approach where few strategies have been examined like intra-aortic ballon pumping or postconditioning. Finally, we provide an algorithm for treating a no-reflow even though no studies showed a beneficial effect in terms of clinical endpoints.
Keywords: No-reflow, slow-flow, myocardial infarction, reperfusion
Current Vascular Pharmacology
Title:Myocardial No-Reflow Treatment
Volume: 11 Issue: 2
Author(s): Olivier Muller, Catalina Trana and Eric Eeckhout
Affiliation:
Keywords: No-reflow, slow-flow, myocardial infarction, reperfusion
Abstract: No-reflow phenomenon is a consequence of percutaneous coronary intervention (PCI) which arises most of the time in the setting of myocardial infarction, but can be also the consequence of PCI in stable angina patients (rotatablator ablation technique or angioplasty in saphenous vein grafts). In this review, we summarize two ways of treating the noreflow according to the current literature. First through the pharmacological approach where several compounds have been assessed like adenosine, nitruprusside, verapamil, nicorandil, dipyridamole, epinephrine or cyclosporine. Second through the mechanical approach where few strategies have been examined like intra-aortic ballon pumping or postconditioning. Finally, we provide an algorithm for treating a no-reflow even though no studies showed a beneficial effect in terms of clinical endpoints.
Export Options
About this article
Cite this article as:
Muller Olivier, Trana Catalina and Eeckhout Eric, Myocardial No-Reflow Treatment, Current Vascular Pharmacology 2013; 11 (2) . https://dx.doi.org/10.2174/1570161111311020015
DOI https://dx.doi.org/10.2174/1570161111311020015 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Adipocytokines in Hepatic Fibrosis
Current Pharmaceutical Design Long Non-coding RNA Therapeutics: Recent Advances and Challenges
Current Drug Targets Paracrine Mechanisms Involved in Mesenchymal Stem Cell Differentiation into Cardiomyocytes
Current Stem Cell Research & Therapy Epidemiology, Evolution, Transmission, and Therapeutics of COVID-19 Outbreak: An Update on the Status
Coronaviruses Elevated Serum Homocysteine Associated with Distal Type of Single Small Subcortical Infarction
Current Neurovascular Research Pathophysiology of Thrombosis in Peripheral Artery Disease
Current Vascular Pharmacology New Therapeutic Aspects of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Conantokins Inhibitors of Ion Flow through the N-Methyl-D-Aspartate Receptor Channels
Current Drug Targets Structures Required of Polyphenols for Inhibiting Advanced Glycation end Products Formation
Current Drug Metabolism Prevalence of Amiodarone Induced Hypothyroidism and Hyperthyroidism in Patients with Heart Diseases: A Systematic Review and Meta-Analysis
Current Medicinal Chemistry Editorial (Hot Topic: Central Blood Pressure: Current Status and Future Perspective)
Current Hypertension Reviews Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Adenosine and Adenosine 5’-triphosphate Catabolism in Systemic Blood as a Potential Biomarker for Doxorubicin Cardiotoxicity in an Experimental Rat Model in vivo
Cardiovascular & Hematological Disorders-Drug Targets Cerebral Hemorrhage Produced by Thrombolytic and Anti-Thrombotic Agents: A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Refining Genetic Approaches for Identifying Behavioral Loci
Current Genomics Biochemical and Pharmacologic Heterogeneity in Low Molecular Weight Heparins. Impact on the Therapeutic Profile
Current Pharmaceutical Design An Updated Review on the Role of Single Nucleotide Polymorphisms in COVID-19 Disease Severity: A Global Aspect
Current Pharmaceutical Biotechnology Heme Oxygenase in Regulation of Renal Function and Blood Pressure
Current Hypertension Reviews A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension
Current Pharmaceutical Design Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets